文献速递肝病消化道肿瘤与早癌

miR-541通过抑制自噬增强人肝细胞癌对索拉非尼治疗的应答

miR-541 potentiates the response of human hepatocellular carcinoma to sorafenib treatment by inhibiting autophagy.
PubMed 文献 · Gut · 2019-11-14

该研究探讨通过调控miR-541启动的microRNA-自噬轴使肝细胞癌(HCC)细胞对索拉非尼敏感的可行性。功能获得与缺失实验表明miR-541抑制HCC细胞生长、转移和自噬,并直接靶向ATG2A和RAB1B。miR-541高表达预示对索拉非尼更好的应答,联合治疗在体内进一步抑制肿瘤生长。

要点

  • miR-541在HCC组织中下调,与恶性临床病理表型、复发和生存相关。
  • miR-541直接靶向ATG2A和RAB1B,抑制HCC细胞生长、转移和自噬。
  • miR-541高表达预示索拉非尼更好应答,联合治疗在体内进一步抑制肿瘤生长。

核心结论

  • miR-541-ATG2A/RAB1B轴失调在患者对索拉非尼治疗的应答中起关键作用。
  • 调控该轴可能改善HCC患者生存,尤其在消除耐药策略的背景下。

研究设计与样本

  • 采用功能获得和缺失实验评估miR-541对人HCC细胞恶性特性和自噬的影响。
  • 通过LC3蛋白印迹、透射电镜和mRFP-GFP-LC3报告构建体共聚焦显微镜扫描定量自噬。
  • 用荧光素酶报告实验确认miR-541的靶点。
  • 建立HCC异种移植瘤分析miR-541在索拉非尼诱导致死中的作用。

主要发现

  • miR-541在人HCC组织中表达下调,与恶性临床病理表型、复发和生存相关。
  • miR-541在体外和体内均抑制HCC细胞生长、转移和自噬。
  • 预测软件和荧光素酶报告实验鉴定ATG2A和RAB1B为miR-541的直接靶点。
  • 抑制ATG2A或RAB1B抑制HCC细胞恶性表型和自噬,与miR-541模拟物效果一致。
  • siATG2A和siRAB1B部分逆转miR-541抑制剂介导的HCC细胞恶性特性和自噬增强。

临床怎么用

  • miR-541表达水平可能作为HCC患者对索拉非尼应答的预测指标。
  • 联合miR-541与索拉非尼可能增强对HCC生长的抑制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Autophagy participates in the progression of hepatocellular carcinoma (HCC) and the resistance of HCC cells to sorafenib. We investigated the feasibility of sensitising HCC cells to sorafenib by modulating miR-541-initiated microRNA-autophagy axis. DESIGN: Gain- and loss-of-function assays were performed to evaluate the effects of miR-541 on the malignant properties and autophagy of human HCC cells. Autophagy was quantified by western blotting of LC3, transmission electron microscopy analyses and confocal microscopy scanning of mRFP-GFP-LC3 reporter construct. Luciferase reporter assays were conducted to confirm the targets of miR-541. HCC xenograft tumours were established to analyse the role of miR-541 in sorafenib-induced lethality. RESULTS: The expression of miR-541 was downregulated in human HCC tissues and was associated with malignant clinicopathologic phenotypes, recurrence and survival of patients with HCC. miR-541 inhibited the growth, metastasis and autophagy of HCC cells both in vitro and in vivo. Prediction software and luciferase reporter assays identified autophagy-related gene 2A (ATG2A) and Ras-related protein Rab-1B (RAB1B) as the direct targets of miR-541. Consistent with the effects of the miR-541 mimic, inhibition of ATG2A or RAB1B suppressed the malignant phenotypes and autophagy of HCC cells. Furthermore, siATG2A and siRAB1B partially reversed the enhancement of the malignant properties and autophagy in HCC cells mediated by the miR-541 inhibitor. More interestingly, higher miR-541 expression predicted a better response to sorafenib treatment, and the combination of miR-541 and sorafenib further suppressed the growth of HCC cells in vivo compared with the single treatment. CONCLUSIONS: Dysregulation of miR-541-ATG2A/RAB1B axis plays a critical role in patients' responses to sorafenib treatment. Manipulation of this axis might benefit survival of patients with HCC, especially in the context of the highly pursued strategies to eliminate drug resistance.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Xu WP, Liu JP, Feng JF, et al. miR-541 potentiates the response of human hepatocellular carcinoma to sorafenib treatment by inhibiting autophagy. Gut. 2019. PMID: 31727683. doi:10.1136/gutjnl-2019-318830

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。